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Manuscript
Cardiovascular (CV) disease remains the biggest cause of morbidity and mortality in 
patients with type 2 diabetes (T2D).1 Individual drugs from two classes of glucose-
lowering agents, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-
glucose cotransporter-2 inhibitors (SGLT2is), have demonstrated improved CV outcomes 
in high CV-risk subjects with T2D. This is reflected in recently updated guidelines from 
several professional associations – but not in the National Institute for Health and Care 
Excellence (NICE) guidelines in the UK.2 We believe that NICE and other 
national/international health authorities need the ability to respond rapidly to new data, 
particularly when there is potential to improve outcomes and save lives. 
Eight CV outcome trials (CVOTs) have already reported1 and more are due to report as 
soon as this year, including CANVAS with canagliflozin, an SGLT2i (clinicaltrials.gov). 
Flexibility in the Food and Drug Administration (FDA) 2008 guidelines3 on how to design, 
perform and analyse these CVOTs (resulting in different trial designs, patient populations 
and definitions of high-risk patients) has made these trials difficult to compare. Despite 
these discrepancies, so far all published trials have demonstrated CV safety in high-risk 
individuals, and three (EMPA-REG OUTCOME with an SGLT2i, empagliflozin [2015] and 
LEADER and SUSTAIN-6 with GLP-1RAs, liraglutide and semaglutide, respectively [both 
2016]) have also demonstrated CV protection (although superiority was not pre-specified 
in SUSTAIN-6).1,4  
In early 2017, the American Diabetes Association (ADA) published updated Standards of 
Medical Care in Diabetes, recommending empagliflozin and liraglutide in patients with CV 
disease, to reduce the mortality risk in these patients.5 Several national guidelines, 
including those from Switzerland and Canada, have also responded quickly to these new 
data. However, NICE in the UK has not yet responded to this evidence, despite EMPA-REG 
OUTCOME being published three months before the most recent NICE guidance in 2015 
(NG28). Concerning liraglutide use, NG28 requires urgent revisiting, given the evidence 
from LEADER in 2016 that liraglutide has shown CV benefit, including reduced mortality.1  
NG28 in 2015 stated that areas ‘that have not been reviewed may be addressed in 2 
years’ and NICE would consider a standing update committee for diabetes, which would 
enable a more rapid update as and when new and relevant evidence is published.2 These 
aspirations appear to have emerged; a committee has met, and the update will be 
published in December 2017. However, previously, NICE has been reluctant to consider 
unlicensed indications, data published after their review process has started and, critically, 
to make any changes based on single studies; to satisfy the improved timescale for 
change, NICE may need to consider breaking these self-imposed rules. 
To conclude, when trials demonstrate the potential for therapies to significantly improve 
clinical practice and patient outcomes, health advisory bodies have a duty of care, not only 
to be thorough and astute, but to fast-track their processes for consideration of the clinical 
implications of potentially important new data on managing patients at considerable risk of 
death or severe disability. Health authorities need to be able to review such data rapidly to 
consider whether such patients might benefit from the CV protection that these potentially 
major medical breakthroughs might offer. 
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*Manuscript with revisions highlighted
The risk of cCardiovascular (CV) disease remains the biggest cause of morbidity and 
mortality higher in patients with type 2 diabetes (T2D) than in those without the disease.1 
Cardiovascular disease (CVD) remains the leading cause of mortality in patients with type 
2 diabetes (T2D) in the UK and elsewhere. Data from the Health Survey for England and 
Scottish Health Survey cohorts indicate that nearly half of subjects with T2D die from 
CVD.1  Individual dDrugs from T two relatively new classes of glucose-lowering agents, 
glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 
inhibitors (SGLT2is), have demonstrated improved cardiovascular (CV) outcomes in high 
CV-risk subjects with T2D. This is reflected in recently updated guidelines from several 
professional associations – but not in the National Institute for Health and Care Excellence 
(NICE) guidelines in the UK.212 This commentary discusses why wWe believe that NICE 
and other national/ and international health authorities need the ability to respond rapidly 
to new data, particularly when there is the potential to improve outcomes and save lives. 
Concerns regarding adverse CV outcomes in a meta-analysis of rosiglitazone trials,3 as 
well as increased mortality in the ‘Action to Control Cardiovascular Risk in Diabetes’ 
(ACCORD) trial, led the Food and Drug Administration (FDA) in the US to issue a ‘Guidance 
for Industry’ in 2008 for evaluating CV safety for new anti-diabetes therapies.4,5 Since this 
guidance was released, eEight CV outcome trials (CVOTs) of glucose-lowering agents have 
already reported (three for dipeptidyl peptidase-4 inhibitors [DPP-4is], three for GLP-1RAs, 
one with an SGLT2i, and one with a long-acting insulin analogue).521 and   Many more 
CVOTs are due to report as soon as this year, including CANVAS with canagliflozin, 
another SGLT2i (clinicaltrials.gov). 
 The fFlexibility in the Food and Drug Administration (FDA) 2008 guidelines34 on how to 
design, perform and analyse these CVOTs (resultinged in different trial designs, patient 
populations and definitions of high-risk patients), hasve mademaking these trials difficult 
to compare. However, dDespite these discrepancies, so far all published trials for DPP-4is, 
GLP-1RAs and an SGLT2i have demonstrated CV safety (non-inferiority) in high-risk 
individuals, and three (EMPA-REG OUTCOME with an SGLT2i, empagliflozin [2015] and 
LEADER and SUSTAIN-6 with GLP-1RAs, liraglutide and semaglutide, respectively [both 
2016]) have also demonstrated CV protection (although superiority was not pre-specified 
in SUSTAIN-6).21,45  
At the beginning ofIn early 2017, the American Diabetes Association (ADA) published 
updated Standards of Medical Care in Diabetes, recommending empagliflozin and 
liraglutide in patients with CVDCV disease, to reduce the mortality risk in these patients.65 
Several national guidelines, , including those from Switzerland7 and Canada,8 including 
those from Switzerland and Canada, have also been quick to responded quickly to these 
new data., making firm recommendations to prioritise liraglutide and empagliflozin in 
patients with CVD. However, NICE in the UK has not yet responded to this evidence, 
despite EMPA-REG OUTCOME being published three months before the most recent NICE 
guidance in 2015 (NG28). Concerning liraglutide use, current NICE guidelinesNG28 
requires urgent revisiting particularly with regard to the 1.8mg dose, given the evidence 
from LEADER in 2016 that liraglutide has shown CV benefit, including reduced mortality.521 
Additionally, the ‘continuation’ rules for GLP-1RAs appear paradoxical, requiring both a 
minimum drop in glycated haemoglobin (HbA1c) and weight loss, without evidence that the 
benefits are restricted to these circumstances.9 The guidelines also currently adopt a 
‘waiting for failure’ approach after the first intensification step, only recommending 
intensification when HbA1c is 7·5% or higher. This is not an appropriate target for many 
patients, particularly those that are younger and more recently diagnosed with T2D.  
When NICE published NG28 in 2015, it stated that areas ‘that have not been reviewed 
may be addressed in 2 years’ and iNICEt would consider a standing update committee for 
diabetes, which would enable a more rapid update, as and when new and relevant 
evidence iwasis published.212 These aspirations appear to have emerged; a committee has 
met, and the update will be published in December 2017. However, this will be over two 
years after EMPA-REG OUTCOME was published, and 11 months after empagliflozin’s EU 
licence update. Additionally, to satisfy this timescale for change, NICE will need to break 
self-imposed rules. However, pPreviously, NICE has been reluctant to consider unlicensed 
indications, data published after their review process has started and, critically, to make 
anymake any  changes based on single studies; to satisfy the improvedis timescale for 
change, NICE will may need to consider breaking these self-imposed rules..  
Since these CVOTs are all single studies, this could mean that all of these compelling data 
are ignored. Additionally, CANVAS will only be published after the NICE reviewing process 
has started, liraglutide awaits a licence update following LEADER and semaglutide is 
currently unlicensed. The CV outcome differences between GLP-1RAs would require NICE 
(and other national and international guidelines, many of which may be awaiting the 
decisions of NICE) to recommend individual drugs, rather than making recommendations 
on drug class.  
To conclude, when trials demonstrate the potential for therapies to significantly improve 
clinical practice and patient outcomes, (such as reductions in major adverse CV events, 
including mortality beyond 30%),  health authorities advisory bodies have a duty of care, 
not only to be thorough and astute, but to fast-track their processes for consideration of 
the clinical implications of potentially important new data on management ofmanaging 
patients at considerable risk of death or severe disability.  Health authorities need to be 
able to review such data rapidly to consider whether such patients might benefit from the 
CV protection that these potentially major medical breakthroughs might offer. 
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